Fig. 3.

Area under the drug plasma concentration–time curve and maximum observed drug plasma concentration during the dosing interval Week 30–32 (pharmacokinetic set^a)^b. ^aAll patients who received study treatment and for whom at least one primary pharmacokinetic parameter was available. ^bAnalyzed using an ANCOVA model, accounting for the impact of treatment (switching vs continuous arms), logarithm of PASI improvement (the ratio of PASI response at Week 14 and at Week 1), weight at Week 14, stage (prior to or after the blinded sample size reassessment), and AUC_τ,12–14 or C_max,12–14. AUC area under the concentration–time curve, CI confidence interval, C_max maximum observed adalimumab plasma concentration, PASI Psoriasis Area and Severity Index